Dietary fructose as a risk factor for non-alcoholic fatty liver disease (NAFLD) - PubMed (original) (raw)
Review
. 2017 Apr;91(4):1545-1563.
doi: 10.1007/s00204-016-1892-7. Epub 2016 Dec 19.
Affiliations
- PMID: 27995280
- DOI: 10.1007/s00204-016-1892-7
Review
Dietary fructose as a risk factor for non-alcoholic fatty liver disease (NAFLD)
Salamah Mohammad Alwahsh et al. Arch Toxicol. 2017 Apr.
Abstract
Glucose is a major energy source for the entire body, while fructose metabolism occurs mainly in the liver. Fructose consumption has increased over the last decade globally and is suspected to contribute to the increased incidence of non-alcoholic fatty liver disease (NAFLD). NAFLD is a manifestation of metabolic syndrome affecting about one-third of the population worldwide and has progressive pathological potential for liver cirrhosis and cancer through non-alcoholic steatohepatitis (NASH). Here we have reviewed the possible contribution of fructose to the pathophysiology of NAFLD. We critically summarize the current findings about several regulators, and their potential mechanisms, that have been studied in humans and animal models in response to fructose exposure. A novel hypothesis on fructose-dependent perturbation of liver regeneration and metabolism is advanced. Fructose intake could affect inflammatory and metabolic processes, liver function, gut microbiota, and portal endotoxin influx. The role of the brain in controlling fructose ingestion and the subsequent development of NAFLD is highlighted. Although the importance for fructose (over)consumption for NAFLD in humans is still debated and comprehensive intervention studies are invited, understanding of how fructose intake can favor these pathological processes is crucial for the development of appropriate noninvasive diagnostic and therapeutic approaches to detect and treat these metabolic effects. Still, lifestyle modification, to lessen the consumption of fructose-containing products, and physical exercise are major measures against NAFLD. Finally, promising drugs against fructose-induced insulin resistance and hepatic dysfunction that are emerging from studies in rodents are reviewed, but need further validation in human patients.
Keywords: ATP; Biomarkers; Ethanol; Gut microbiota; Herbal medicine; Humans; Inflammation; Insulin resistance; Liver regeneration; Metabolic syndrome (MetS); Oxidative stress; The brain.
Similar articles
- The FATZO mouse, a next generation model of type 2 diabetes, develops NAFLD and NASH when fed a Western diet supplemented with fructose.
Sun G, Jackson CV, Zimmerman K, Zhang LK, Finnearty CM, Sandusky GE, Zhang G, Peterson RG, Wang YJ. Sun G, et al. BMC Gastroenterol. 2019 Mar 18;19(1):41. doi: 10.1186/s12876-019-0958-4. BMC Gastroenterol. 2019. PMID: 30885145 Free PMC article. - Fructose and liver function--is this behind nonalcoholic liver disease?
Jin R, Vos MB. Jin R, et al. Curr Opin Clin Nutr Metab Care. 2015 Sep;18(5):490-5. doi: 10.1097/MCO.0000000000000203. Curr Opin Clin Nutr Metab Care. 2015. PMID: 26203597 Review. - Fructose as a key player in the development of fatty liver disease.
Basaranoglu M, Basaranoglu G, Sabuncu T, Sentürk H. Basaranoglu M, et al. World J Gastroenterol. 2013 Feb 28;19(8):1166-72. doi: 10.3748/wjg.v19.i8.1166. World J Gastroenterol. 2013. PMID: 23482247 Free PMC article. Review.
Cited by
- Serine catabolism generates liver NADPH and supports hepatic lipogenesis.
Zhang Z, TeSlaa T, Xu X, Zeng X, Yang L, Xing G, Tesz GJ, Clasquin MF, Rabinowitz JD. Zhang Z, et al. Nat Metab. 2021 Dec;3(12):1608-1620. doi: 10.1038/s42255-021-00487-4. Epub 2021 Nov 29. Nat Metab. 2021. PMID: 34845393 Free PMC article. - Fibroblast growth factor signaling in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: Paving the way to hepatocellular carcinoma.
Ocker M. Ocker M. World J Gastroenterol. 2020 Jan 21;26(3):279-290. doi: 10.3748/wjg.v26.i3.279. World J Gastroenterol. 2020. PMID: 31988589 Free PMC article. Review. - The Metalloproteinase ADAM28 Promotes Metabolic Dysfunction in Mice.
Herat L, Rudnicka C, Okada Y, Mochizuki S, Schlaich M, Matthews V. Herat L, et al. Int J Mol Sci. 2017 Apr 21;18(4):884. doi: 10.3390/ijms18040884. Int J Mol Sci. 2017. PMID: 28430139 Free PMC article. - Fructose Consumption, Lipogenesis, and Non-Alcoholic Fatty Liver Disease.
Ter Horst KW, Serlie MJ. Ter Horst KW, et al. Nutrients. 2017 Sep 6;9(9):981. doi: 10.3390/nu9090981. Nutrients. 2017. PMID: 28878197 Free PMC article. Review. - Aberrant Lipid Metabolism in Hepatocellular Carcinoma Revealed by Liver Lipidomics.
Li Z, Guan M, Lin Y, Cui X, Zhang Y, Zhao Z, Zhu J. Li Z, et al. Int J Mol Sci. 2017 Nov 28;18(12):2550. doi: 10.3390/ijms18122550. Int J Mol Sci. 2017. PMID: 29182572 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical